Poniard Pharmaceuticals and AltheaDx Sign Agreement
News Apr 15, 2008
Although platinum-based therapy is the standard of care for a broad range of solid tumors, its efficacy in most cancers is limited by the development of platinum resistance. Picoplatin, Poniard's lead product candidate, is a new generation platinum agent designed to overcome platinum resistance. The development of molecular signatures of platinum resistance may allow the prediction of clinical response to picoplatin treatment and may improve outcomes for patients with platinum-resistant cancers.
"We hope to better understand some of the biological mechanisms behind cancer's resurgence after platinum treatment, a significant treatment limiting problem for many patients with solid tumors," said Jerry McMahon, Chairman and CEO of Poniard Pharmaceuticals. "AltheaDx's high throughput gene expression platform facilitates the identification of molecular signature of platinum resistance that can guide therapeutic choices."
"Our mission at AltheaDx is to bring cancer diagnostics into clinical use," said David Macdonald, CEO of AltheaDx. "We are excited about Poniard's choice of our Express Pathway program to expedite identification, validation, and delivery of clinically valid molecular biomarkers to help guide more informed therapeutic decisions."
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE